In the experimental group, a neoantigen peptide vaccine (LLCvac) consisting of 7 identified neoantigen peptides (100 μg/peptide/mouse) combined with an optimized clinically available dual immune adjuvants [50 μg Poly(I:C) + 50 μg thymosin alpha-1(ZadaxiN, Sciclone pharmaceuticals, USA)] was administered subcutaneously to the tumor-bearing mice starting on day 0, once every four days for three times. Here, PTMA is linked to neoplasm.